《大行報告》大摩:藥明康德(02359.HK)積極回購A股反映管理層認為股票被低估
摩根士丹利發表報告,給予藥明康德A股(603259.SH)「增持」評級,行業前景「吸引」,目標價151元人民幣。
大摩指公司近日再通過一項10億人民幣的A股股份回購計劃。這是繼美國提出《生物安全法案》草案後,公司第二次A股回購計劃。根據公司披露,藥明康德將在未來3個月內回購約1,200萬股A股,即其總發行股份(29.53億股)的0.41%,回購價不高於每股83.33元人民幣。大摩認為公司連續進行股票回購,展現了在動盪市場中保護股東利益的堅定意願,並反映了管理層認為公司股票被低估。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.